Summary
When a 35-year-old man with essential hypertension was treated with antibiotics for brucellosis his blood pressure rose significantly. While all other treatment was kept constant rifampicin was discontinued. On rechallenge rifampicin did not alter serum concentrations of enalapril or the area under the curve (AUC) between 0 and 7 h, but it did reduce the AUC of the active metabolite enalaprilat by 31%. These observations suggest that there may be an interaction between rifampicin and enalapril, causing reduced hypotensive efficacy of enalapril. The mechanism of such an interaction merits further study, but it could be due to enhanced renal clearance of enalaprilat.
This is a preview of subscription content, log in via an institution to check access.
References
Hichens M, Hand EL, Mulcahy WS (1981) Radioimmunoassay for angiotensin converting enzyme inhibitors. Ligand Q 4: 43
Ohnhaus EE, Kirchhof B, Peheim E (1979) Effect of enzyme induction on plasma lipids using antipyrine, phenobarbital and rifampicin. Clin Pharmacol Ther 25: 591–597
Ulm EH (1983) Enalapril maleate (MK-421), a potent nonsulphhydryl angiotensin-converting enzyme inhibitor: absorption, disposition and metabolism in man. Drug Metab Rev 14: 99–110
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kandiah, D., Penny, W.J., Fraser, A.G. et al. A possible drug interaction between rifampicin and enalapril. Eur J Clin Pharmacol 35, 431–432 (1988). https://doi.org/10.1007/BF00561378
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561378